Brean Capital set a $14.00 price target on Trevena Inc. (NASDAQ:TRVN) in a research note issued to investors on Monday. The brokerage currently has a a buy rating on the biopharmaceutical company’s stock.
Other equities research analysts have also issued reports about the stock. Cowen and Company reaffirmed a buy rating and set a $13.00 price objective on shares of Trevena in a report on Friday, August 5th. FBR & Co reaffirmed a buy rating and set a $13.00 price objective on shares of Trevena in a report on Thursday, August 4th. Zacks Investment Research raised shares of Trevena from a sell rating to a hold rating in a report on Wednesday, July 20th. Jefferies Group reaffirmed a buy rating on shares of Trevena in a report on Friday, August 5th. Finally, TheStreet lowered shares of Trevena from a hold rating to a sell rating in a report on Friday, June 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $14.30.
Trevena (NASDAQ:TRVN) opened at 6.73 on Monday. Trevena has a 52 week low of $5.58 and a 52 week high of $13.02. The company has a 50 day moving average of $6.96 and a 200 day moving average of $7.21. The stock’s market capitalization is $351.16 million.
Trevena (NASDAQ:TRVN) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by $0.01. Trevena had a negative net margin of 841.00% and a negative return on equity of 45.01%. Equities analysts expect that Trevena will post ($1.55) EPS for the current fiscal year.
A number of hedge funds have recently modified their holdings of TRVN. National Planning Corp increased its stake in shares of Trevena by 21.9% in the first quarter. National Planning Corp now owns 19,452 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 3,500 shares in the last quarter. Alliancebernstein L.P. bought a new stake in shares of Trevena during the second quarter worth about $163,000. Highbridge Capital Management LLC bought a new stake in shares of Trevena during the second quarter worth about $225,000. Metropolitan Life Insurance Co. NY increased its stake in shares of Trevena by 54.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 35,964 shares of the biopharmaceutical company’s stock worth $227,000 after buying an additional 12,694 shares in the last quarter. Finally, Guggenheim Capital LLC bought a new stake in shares of Trevena during the second quarter worth about $259,000. Institutional investors own 75.43% of the company’s stock.
Trevena Company Profile
Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.
Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.